Meta-analysis of ischemic stroke or systemic embolism.

<p>There was no difference in the rate of major bleeding [OR 1.06 (95% CI 0.42–2.62); I² 0%] or vascular death [OR 1.04 (95% CI 0.61–1.75); I² 1%] but patients treated with aspirin had an increased risk in all-cause mortality [OR 1.66 (95% CI 1.12–2.48); I² 0%] (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142222#pone.0142222.g003" target="_blank">Fig 3</a>). The difference in all-cause mortality was driven by an increased risk in non-vascular death in patients treated with aspirin [OR 3.20(95% CI 1.31–7.82); I² 0%], whereas the risk for death from unknown causes not significantly different [OR 1.525 (95% CI 0.65–3.55; I² 0%]. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142222#pone.0142222.t004" target="_blank">Table 4</a> provides the number of events in each study.</p

Quality assessment.

<p>AFASAK: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation; PATAF: Primary Prevention of Arterial Thromboembolism in patients with Non-rheumatic Atrial Fibrillation in Primary Care</p><p>Quality assessment.</p

Characteristics of the studies included in the main analysis.

<p>AFASAK: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation;</p><p>PATAF: Primary Prevention of Arterial Thromboembolism in patients with Non-rheumatic Atrial Fibrillation in Primary Care;</p><p>HTN: Hypertension; DBT: Diabetes; HF: Heart Failure; TTR: Time in therapeutic range</p><p>Characteristics of the studies included in the main analysis.</p

Current recommendation for the use of aspirin in patients with non-valvular atrial fibrillation.

<p>OAC: Oral anticoagulation; AF: Atrial Fibrillation</p><p>Current recommendation for the use of aspirin in patients with non-valvular atrial fibrillation.</p

All cause mortality meta-analysis.

<p>The addition of a study arm from the AFASAK study [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142222#pone.0142222.ref013" target="_blank">13</a>] comparing aspirin vs. low-intensity anticoagulation plus aspirin did not modify any of the estimates including the reduction in all-cause mortality [OR 1.66(95% CI 1.15–2.38); I² 0%]. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142222#pone.0142222.t003" target="_blank">Table 3</a> presents a summary of the number of individual events from each study.</p

Prevalence and Geographical Variation of Prothrombin G20210A Mutation in Patients with Cerebral Vein Thrombosis: A Systematic Review and Meta-Analysis

<div><p>Objectives</p><p>To compare the prevalence of prothrombin G20210A in patients with objectively confirmed cerebral vein or cortical vein thrombosis against healthy controls, and evaluate geographical variations.</p><p>Design</p><p>Systematic review and meta-analysis of case control studies.</p><p>Methods</p><p>We conducted a systematic review of electronic databases including MEDLINE and EMBASE. The main outcome was the prevalence of prothrombin G20210A in patients with objectively confirmed cerebral vein or cortical vein thrombosis; we also analyzed individual country variations in the prevalence. The random-effects model OR was used as the primary outcome measure.</p><p>Results</p><p>In total 19 studies evaluated 868 cases of cerebral venous thrombosis and 3981 controls. Prothrombin G20210A was found in 103/868 of the patients with cerebral venous thrombosis and 105/3999 of the healthy controls [random effects pooled OR 5.838, 95% CI 3.96 to 8.58; I²17.9%]. The prevalence of prothrombin G20210A was significantly elevated in Italian studies (OR 9.69), in Brazilian studies (OR 7.02), and in German studies (OR 3.77), but not in Iranian studies (OR 0.98).</p><p>Conclusion</p><p>Prothrombin G20210A is significantly associated with cerebral venous thrombosis when compared to healthy controls, although this association is highly dependent on the country of origin.</p></div

Meta-analysis and individual study data.

<p>Meta-analysis and individual study data.</p

Forest plot prevalence of prothrombin G20210A.

<p>Forest plot prevalence of prothrombin G20210A.</p

L’Abbé bias plot.

<p>L’Abbé bias plot.</p

Characteristics of the studies included.

<p>Characteristics of the studies included.</p